Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Board Appointment

25 Jun 2008 13:53

RNS Number : 5191X
CareCapital Group plc
25 June 2008
 

CARECAPITAL GROUP PLC

("CareCapital" or "the Company")

Board Appointment

CareCapital plc (AIMCARE), the healthcare real estate developer and owner, announces that Margaret McDonagh has joined the Board of the Company as a Non Executive Director, with immediate effect.

During her varied and highly successful career to date, Ms Margaret McDonough BSc MA, 46, has held a range of senior positions within both public and private organisations. She is currently a Non Executive Director of both Standard Life plc, having been appointed to the Board in February 2007 following the company's demutualisation, and TBI Plc, a major airport owner in Europe and the Americas. Margaret was also a Director and Founder of BBM Consultants Ltd , and Chief Executive Officer of AM Creative Ltd, a talent management agency.

Prior to this, Margaret enjoyed an illustrious 15 year career with the Labour Party, which culminated in her becoming both the first female, and youngest ever General Secretary of the Party in 1998. She took up this post after having acted as General Election Coordination for Labour's landslide General Election victory in 1997. Margaret worked closely with the Prime Minister during the Party's first term and through its second landslide General Election victory in 2001. She is now a life peer in the House of Lords.

Commenting on the appointment, Paul Stacey, Managing of CareCapital said: "I am delighted to welcome Margaret to the company. She brings a wealth of experience and will undoubtedly be a great asset to the Board of CareCapital as we continue to grow the business and create value for shareholders."

For further information please visit www.carecapital.co.uk or contact:

Paul Stacey, Managing Director

Shareen Courtney, Marketing 

Lindsay Mair, Director - Corporate Finance

Simon Hudson, 

Paul Youens, Paul Young

CareCapital Group Plc

Daniel Stewart & Company  plc

Tavistock Communications

Tel: 020 7034 1949

Tel: 020 7776 6550

Tel: 020 7920 3150

or 07966 477256

pstacey@carecapital.co.uk

lindsay.mair@danielstewart.co.uk

shudson@tavistock.co.uk 

scourtney@carecapital.co.uk

pyouens@tavistock.co.uk

pyoung@tavistock.co.uk

Additional Disclosures

Margaret  holds, or has held, the following directorships and partnerships within the past five years: 

Current directorships / partnerships:

TBI plc

AM Creative Ltd

Standard Life Plc

Past directorships / partnerships:

Newspapers Publishers Association Limited

Catz Club

BBM Consultants Limited

Save for the information disclosed above there is no other information to be disclosed under schedule two, paragraph (g) of the AIM Rules.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABDGDLBUDGGIU
Date   Source Headline
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
7th Aug 20197:00 amRNSIssue of equity and new debt facility
6th Aug 201911:05 amRNSSecond Price Monitoring Extn
6th Aug 201911:00 amRNSPrice Monitoring Extension
25th Jul 20195:12 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement & Technological update
22nd Jul 20197:00 amRNSHarley Street update
28th Jun 20197:00 amRNSFinal Results
3rd Jun 20197:00 amRNSTechnological update
31st May 20195:30 pmRNSTotal Voting Rights
17th May 20195:29 pmRNSHolding(s) in Company
16th May 20192:23 pmEQSAdvanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
13th May 201912:20 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology
10th May 20197:00 amRNSDebt facility secured
16th Apr 201910:26 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
16th Apr 20199:12 amEQSAdvanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
16th Apr 20197:00 amRNSSenior Management Appointment
7th Mar 20199:00 amRNSPrice Monitoring Extension
22nd Feb 20197:00 amRNSGrant of options
1st Feb 20197:00 amRNSAppointment of Nominated Adviser and Joint Broker
30th Jan 201911:45 amRNSSchedule 2(g) Disclosure
29th Jan 20199:38 amRNSTotal Voting Rights and Significant Shareholdings
24th Jan 201912:14 pmRNSSchedule 2(g) Disclosure
22nd Jan 20193:29 pmRNSResult of General Meeting
21st Jan 201911:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
21st Jan 20197:00 amRNSISO 13485:2016 certification for medical devices
21st Dec 201810:15 amRNSLaunch of 2018 SAYE Scheme
21st Dec 20187:00 amRNSProposed Direct Subscription to raise £10.0m
16th Oct 20184:31 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
16th Oct 20183:58 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
10th Oct 20187:30 amRNSGPSL Research - Flash Note on AVO
10th Oct 20187:00 amRNSTechnological update
4th Oct 201811:07 amRNSGPSL Research - Flash Note on AVO
28th Sep 20187:00 amRNSHalf-year Report
27th Sep 20187:00 amRNSTechnological update
10th Sep 201811:32 amRNSHolding(s) in Company
7th Sep 201811:52 amRNSHolding(s) in Company
3rd Sep 20185:15 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
3rd Sep 201811:38 amRNSCompletion of the £6.41m Placing
29th Aug 20189:57 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
28th Aug 20187:00 amRNSDirector Declaration
9th Aug 20187:00 amRNSExercise of Warrants and Issue of Shares
2nd Aug 20187:00 amRNS£6.41m Placing
25th Jul 20183:34 pmRNSResult of AGM
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
4th Jul 201811:05 amRNSSecond Price Monitoring Extn
4th Jul 201811:00 amRNSPrice Monitoring Extension
4th Jul 20189:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.